TScan Therapeutics, Inc.
TCRX
$1.82
$0.084.60%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 41.69% | 226.47% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 41.69% | 226.47% | |||
| Cost of Revenue | 9.55% | 140.72% | |||
| Gross Profit | -7.03% | -137.41% | |||
| SG&A Expenses | 5.35% | 7.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.61% | 2.79% | |||
| Operating Income | -6.63% | 1.26% | |||
| Income Before Tax | -8.28% | 4.70% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -8.28% | 4.70% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.28% | 4.70% | |||
| EBIT | -6.63% | 1.26% | |||
| EBITDA | -6.70% | 1.19% | |||
| EPS Basic | -7.98% | 4.69% | |||
| Normalized Basic EPS | -7.99% | 1.70% | |||
| EPS Diluted | -7.98% | 4.69% | |||
| Normalized Diluted EPS | -7.99% | 1.70% | |||
| Average Basic Shares Outstanding | 0.28% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.28% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||